Chronic lymphocytic leukemia (CLL) is a B-cell malignancy characterized by the accumulation of a population of CD5 þ / CD23 þ mature B lymphocytes in the peripheral blood, bone marrow and lymph nodes.
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Chronic lymphocytic leukemia (CLL) is a B-cell malignancy characterized by the accumulation of a population of CD5 þ / CD23 þ mature B lymphocytes in the peripheral blood, bone marrow and lymph nodes. 1 In vivo studies have shown that a significant proportion of the leukemic clone renovates daily and that cell proliferation occurs almost exclusively in lymphoid organs. Here, an intense bi-directional crosstalk takes place between the CLL cell and surrounding non-neoplastic lymphoid and stromal elements. 2 The lymph node architecture is then molded into an anatomically defined niche, known as the proliferation center, where the antigen(s) is presented to the neoplastic cell together with a cocktail of soluble and cell-bound accessory signals. 3 The ensuing proliferation may lead to the acquisition of novel genetic lesions or to the expansion of pre-existing leukemic subclones harboring deleterious mutations. Hence, therapeutic strategies aimed at preventing localization to these growth-privileged areas may enhance efficacy of conventional chemotherapies.
Our original interest in CLL derives from the observation that CD38, an ectoenzyme and a receptor is a negative prognostic marker for CLL patients. The finding that CD38 is expressed by a subset of CLL cells characterized by a more aggressive course of the leukemia, with a shorter time to first treatment and a shorter overall survival, posed the logical question of whether the molecule is directly involved in determining a worse clinical outcome or whether it is simply an epiphenomenon of other events. 4 A genome-wide signature of the events controlled by the CD38 pathway clearly pointed to the activation of motility programs as the main characterizing element. 5 Our hypothesis is that CD38 acts as a facilitator of the homing process of CLL cells, by actively guiding them to growth-favorable niches, mainly located in lymphoid organs. 6 To corroborate the involvement of CD38 in CLL trafficking, the homing process was dissected into distinct events and the role of the molecule examined in each of them separately. Previous evidence indicates that CD38 enhances CXCL12 sensitivity, 7 as well as CD49d-mediated adhesion, 8 suggesting that chemotaxis and adhesion can be modulated by CD38 expression. The question behind the present work is whether degradation of the extracellular matrix, the final step in the homing cascade, is also differentially active in CD38 þ -vs CD38 À -CLL patients. To answer this question, the expression and activity of MMP-9 was analyzed by gelatin zymography in a cohort of patients (n ¼ 55, Supplementary Table 1) . A marked heterogeneity in the constitutive expression and function of MMP-9 was highlighted (Figure 1a ). Patients expressing CD38 on more than 20% of the clone were endowed with significantly higher constitutive MMP-9 activity (P ¼ 0.004; Figure 1b Figure 1 . (a, b) Expression and activity of MMP-9 was measured by gelatin zymography in a cohort of CLL patients (n ¼ 55) and quantify, highlighting a statistically significant difference between CD38 þ and CD38 À patients (P ¼ 0.004). (c) Plasma levels of MMP-9 were evaluated by immunoassay in 40 CLL patients highlighting a statistically significant difference (
þ and CD38 À cells from CD38 bimodal patients were sorted with fluorescence-activated cell sorting and the expression of MMP-9 was checked by reverse transcription-PCR. Results showed that CD38 þ subclones display higher level of MMP-9 messenger RNA (Po0.0001). (e, f ) Gelatin zymography assay carried out comparing the CD38 À with the intact clone in CD38 bimodal patients (n ¼ 4) highlighted a loss of activity of MMP-9 in the negative subclone of all patients analyzed (P ¼ 0.021). (g, h) The engagement of CD38 by an agonistic antibody resulted in a time-dependent upregulation of the activity of MMP-9 by CLL cells (P ¼ 0.0002). As expected, exposure to FN (Po0.0001) or CXCL12 (P ¼ 0.0004) also stimulated MMP-9 secretion. (i, j) The exposure of CLL cells to specific inhibitors impacted on MMP-9 secretion: treatment with UO126 resulted in a diminished activity of the gelatinase following CD38 engagement (P ¼ 0.038), while wortmannin had no effect (P ¼ NS).
CLL cells have a greater propensity to digest extracellular matrix than their negative counterparts (Po0.0001; Supplementary Figure 1B and C). A higher expression of MMP-9 in the CD38 þ subset of CLL patients was further confirmed by evaluating its levels in plasma samples collected from 40 independent patients (P ¼ 0.013; Figure 1c ).
CLL patients with bimodal CD38 expression offered the possibility of analyzing MMP-9 expression and activity in CD38 þ and CD38
À subclones against a homogeneous genetic background. 7 Results indicate that the CD38 þ subclone invariably displays higher levels of MMP-9 messenger RNA (n ¼ 8, Po0.0001; Figure 1d ). Furthermore, functional assays showed a marked loss in MMP-9 activity, when CD38 þ cells were deprived from the intact clone (P ¼ 0.021; Figures 1e and f) . The finding that the positive correlation between CD38 and MMP-9 is maintained intraclonally, with the CD38 þ component producing significantly more MMP-9 than the counterpart, strengthens the notion that the dynamic acquisition of CD38 expression by a subset of the leukemic clone is accompanied by an increased ability to recirculate to distinct districts. This indication is in line with independent evidence that (i) CLL cells present in lymph nodes or bone marrow express CD38 at higher levels than circulating leukemic lymphocytes obtained from the same patient at the same time. 9 Moreover, (ii) in vitro and (iii) in vivo studies conclusively showed that the proliferating component of the disease is contained in the CD38 þ subset. 10 Lastly, (iv) studies in patients who were treated with deuterated Figure 2 . CLL cells were left to adhere to recombinant human vascular cell adhesion molecule-1 for 1 h and then stained for CD38, CD49d, CXCR4 (red) and MMP-9 or phosphotyrosine (P-Tyr) (green) and counterstained with DAPI (blue). Confocal microscopy analyses showed a clear co-localization of MMP-9 with CD38, CD49d and CXCR4 in CLL cells in correspondence to the adhesion site and further demonstrated using co-localization scatter-plot analyses. After engagement of the a4b1 integrin by its ligand, a clear co-localization of phosphotyrosine proteins, CD38 and CD49d was visible, suggesting the existence of a supra-molecular complex.
water suggest that CD38 expression defines a subpopulation of cells that has more recently left the lymph node compartment.
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The implication would be that the ability to home to specific niches of a given CLL cell may be transient and likely regulated not only by the genetic architecture of the tumor, but also by environmental factors dependent on the host. To formally prove the link between CD38 and MMP-9, CLL cells were genetically modified for the expression of CD38 using a lentiviral technique. 7 Infection of neoplastic cells (n ¼ 9) with lentiviruses carrying the genetic material for CD38 (S38W) led to a significant increase in the expression of CD38, as confirmed by western blot analyses (Supplementary Figure 2A) . De novo expression of CD38 was accompanied by increased secretion of the active form of MMP-9 (P ¼ 0.0001) in the supernatant. Infection with the empty lentiviruses (SEW) resulted in stronger up-regulation of MMP-9 secretion than keeping CLL cells in culture for the same amount of time (P ¼ 0.02), although at significantly lower levels than when using the S38W virus (P ¼ 0.02; Supplementary Figures 2A and B) . These results support the hypothesis that CD38 directly modulates expression and secretion of the active form of MMP-9.
MMP-9 production peaks during cell homing to different districts. The signals that regulate migration and adhesion, such as the CXCL12 chemokine and the a4b1 integrin, induce MMP-9 secretion by activating distinct intracellular signaling pathways. 12 To determine whether CD38 activation is involved in MMP-9 secretion, CD38 þ -CLL patient samples (surface expression range 35-85%) were treated with an agonistic anti-CD38 monoclonal antibody or irrelevant isotype-matched control. CD38 ligation triggered a marked up-regulation of the secreted form of MMP-9, with a peak after 24 h (n ¼ 6; P ¼ 0.0002 when compared with cells treated with BSA, Figures 1g and h ). As expected, exposure to fibronectin (Po0.0001) or CXCL12 (P ¼ 0.0004) also induced MMP-9 secretion. However, the combination of CD38 with fibronectin or CXCL12 did not result in a synergistic effect, suggesting that each of these signals is independent, or-alternatively-that all signals induce a maximal response, which cannot be enhanced further, at least in this experimental setting.
Consistently, ligation of CD38-induced marked phosphorylation of ERK1/2 and p38 kinases and a limited upregulation of Akt (Supplementary Figure 3A) . The chemokine CXCL12 and the a4b1 integrin induced MMP-9 secretion by activating the ERK1/2 and the PI3-K/Akt signaling pathways, respectively. 12 The use of specific protein kinase inhibitors indicated that CD38-driven up regulation of MMP-9 is dependent upon ERK1/2 activation and independent of PI-3 K. Inhibition of ERK1/2 by UO126 reduced MMP-9 to basal levels (P ¼ 0.038), while exposure to wortmannin had no effect (P ¼ NS; Figures 1i-j) . These results were confirmed using matrix degradation assays (Supplementary Figure 3B) .
We recently reported that upon ligand binding, the CD49d integrin triggers the assembly of podosomes, with a concomitant co-localization of CD38 at the adhesion site in CLL cells. 8 Independent observations, indicate that a supra-molecular complex containing CD38, CD49d, MMP-9 and CD44 is present on the CLL membrane of patients with a poor prognosis. 13 Here we asked whether MMP-9 and CD38 co-localize at the sites of adhesion and invasion. Confocal microscopy analyses showed that, upon binding to fibronectin, CD38 and MMP-9 clustered with CD49d at the adhesion sites. CXCR4 molecules also appeared to be recruited to these domains, suggesting the existence of a supra-molecular complex in CLL cells that can regulate the chemotaxis, adhesion and degradation of extracellular matrix. Moreover, intracellular tyrosine-phosphorylated proteins also appeared enriched at the adhesion sites, associating with CD38 and CD49d and supporting the hypothesis of a dynamic regulation of the complex (Figure 2 ). This observation is in line with previous data indicating that, at variance with normal B lymphocytes, CLL cells form podosomes, 14 adhesive structures that connect extracellular signals with the internal response machinery. The results obtained in this work indicate that adhesion to CD49d ligands leads to the coagulation of a CLL invadosome, a functional structure characterized by the simultaneous presence of the chemokine receptor CXCR4, of the CD49d integrin and of the extracellular matrix-degrading enzyme MMP-9. The additional presence of CD38 in this domain would act as an enhancement factor of chemotaxis, adhesion and matrix digestion, ultimately making homing more efficient.
Taken together, all these observations provide new insights for why CD38 expression in CLL portends a worse clinical outcome. They also offer a rationale for therapeutically targeting CD38 in specific subsets of CLL patients. 15 What remains to be determined from a basic science angle is whether CD38 effects are mediated by its NAD þ -degrading activity or by its signaling properties.
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu) CXCR4 expression in CD34 þ cells and unit predominance after double umbilical cord blood transplantation The applicability of UCB transplantation had been historically limited by the small cell number available from a single unit. 4 Over the past decade, the utilization of double UCB (dUCB) unit grafts was shown to, at least in part, overcome the cell dose limitation and has been adopted by several institutions. 5, 6 Our group 7 and others 5, 8 have shown that despite the infusion of two UCB units, in the vast majority of cases only a single unit will predominate and provide long-term lympho-hematopoietic (FITC, BD Biosciences) and the corresponding fluorochrome-conjugated isotype controls (BD Biosciences). CXCR4 was substituted by CD38 (PE, BD Biosciences) in other tube set. Results were analyzed using FlowJo Software (TreeStar, Ashland, OR, USA). CD34 subpopulation was determined by creating a gate on the lymphocyte population followed by a plot of CD34 (y-axis)/forward scatter to select the single CD34-positive population. Similarly, following the lymphocyte population, a plot of CD34 (y-axis)/CD33 (x-axis) cells was determined to select the double-positive population. Another plot of CD34 (y-axis)/CD38 (x-axis) cells was determined to select the CD34 þ /CD38 À subpopulation (a). Next, a plot of CD34 (y-axis)/CD45 (x-axis) cells was determined to select the double-positive population that represents progenitor/stem cell subpopulation (b). The double-positive population was analyzed for median CXCR4 fluorescence intensity (MFI) and percentage of positive cells (c). Panel (d) shows a representative MFI of two cords infused to a single patient. In panel (e), we show the proportion of cord blood units that predominate long-term by their expression, as measured by the mean fluorescence intensity, of CXCR4 in CD34 þ cells. The open circles represent patient for whom the predominating unit had a similar or similar HLA-match as compared with the non-predominant one; the open circles represent predominating unit that were better HLA matched as compared with the non-predominant one.
Accepted article preview online 7 September 2012; advance online publication, 12 October 2012
